Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis.

BACKGROUND & AIMS The steroid and xenobiotic receptor (SXR) is a ligand-dependent transcription factor that mediates protection against bile acid-induced liver injury in cholestatic animal models. Ursodeoxycholic acid and rifampicin are known ligands. We investigated whether functional polymorphisms of the SXR gene influence disease susceptibility or disease progression in patients with primary sclerosing cholangitis (PSC). METHODS Polymorphisms at 8 loci across the SXR gene were genotyped in 327 Scandinavian PSC patients and 275 healthy controls. Kaplan-Meier survival analyses and Cox regressions were performed to estimate effects from genotypes on patient survival, defined as time from diagnostic cholangiography to death or liver transplantation. RESULTS Susceptibility to PSC was not associated with any of the SXR polymorphisms studied. Median survival was significantly reduced in patients homozygous for the minor allele as compared with patients carrying at least 1 major allele of the neighboring polymorphisms rs6785049 (10.8 vs 14.0 years, respectively, P = .01), rs1054190 (3.6 vs 13.6 years, respectively, P = .004), and rs3814058 (3.5 vs 13.3 years, respectively, P = .01). The increased risk of death or liver transplantation was confirmed in univariate Cox regressions (relative risk [RR](rs6785049) = 1.7, 95% CI: 1.1-2.6; RR(rs1054190) = 3.1, 95% CI: 1.4-7.1; and RR(rs3814058) = 2.2, 95% CI: 1.2-4.2 for the 3 polymorphisms, respectively). In multiple Cox regressions including age at PSC onset, rs1054190 remained an independent risk factor. CONCLUSIONS Functional SXR gene variants appear to modify disease course in PSC. Further investigations of polymorphisms in the SXR gene may provide insight into the prognostic importance of SXR-regulated pathways in this disease, perhaps even in a therapeutic perspective.

[1]  Jiezhong Chen,et al.  Nuclear receptors, bile-acid detoxification, and cholestasis , 2006, The Lancet.

[2]  C. O'Morain,et al.  The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. , 2006, Gastroenterology.

[3]  Denise G. Teotico,et al.  The nuclear xenobiotic receptor pregnane X receptor: recent insights and new challenges. , 2005, Molecular endocrinology.

[4]  K. Chayama,et al.  Glycochenodeoxycholate plays a carcinogenic role in immortalized mouse cholangiocytes via oxidative DNA damage. , 2005, Free radical biology & medicine.

[5]  Michael R Knowles,et al.  Genetic modifiers of lung disease in cystic fibrosis. , 2005, The New England journal of medicine.

[6]  K. Zatloukal,et al.  CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice , 2005, Hepatology.

[7]  J. Boyer.  Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? , 2005, Gastroenterology.

[8]  S. Sahlin,et al.  Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. , 2005, Gastroenterology.

[9]  R. Chapman,et al.  Review article: current management of primary sclerosing cholangitis , 2005, Alimentary pharmacology & therapeutics.

[10]  R. Evans,et al.  Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Bergquist,et al.  Increased prevalence of primary sclerosing cholangitis among first-degree relatives. , 2005, Journal of hepatology.

[12]  S. Kuriyama,et al.  Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis , 2005, Hepatology.

[13]  A. Zinsmeister,et al.  PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis , 2004, Gut.

[14]  Gerd Schmitz,et al.  Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. , 2004, Gastroenterology.

[15]  Vladimir Makarov,et al.  Two methods of whole-genome amplification enable accurate genotyping across a 2320-SNP linkage panel. , 2004, Genome research.

[16]  C. Handschin,et al.  Induction of Drug Metabolism: The Role of Nuclear Receptors , 2003, Pharmacological Reviews.

[17]  Kenichi Yoshida,et al.  Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter , 2003, Journal of Human Genetics.

[18]  J. Boyer,et al.  Bile salt transporters: molecular characterization, function, and regulation. , 2003, Physiological reviews.

[19]  P. McKeigue,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Problems of Reporting Genetic Associations with Complex Outcomes , 2022 .

[20]  G. Abecasis,et al.  Using haplotype blocks to map human complex trait loci. , 2003, Trends in genetics : TIG.

[21]  E. Schrumpf,et al.  Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries , 2003, Scandinavian journal of gastroenterology.

[22]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[23]  A. Bergquist,et al.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. , 2002, Journal of hepatology.

[24]  T. Huizinga,et al.  Six microsatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNF−308A in systemic lupus erythematosus , 2001, Genes and Immunity.

[25]  Jatinder Lamba,et al.  Disrupted Bile Acid Homeostasis Reveals an Unexpected Interaction among Nuclear Hormone Receptors, Transporters, and Cytochrome P450* , 2001, The Journal of Biological Chemistry.

[26]  J. Hudson,et al.  The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. , 2001, Pharmacogenetics.

[27]  P. Donaldson,et al.  Immunogenetics in PSC. , 2001, Best practice & research. Clinical gastroenterology.

[28]  U. Beuers,et al.  Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. , 2001, Liver.

[29]  J. Talwalkar,et al.  Natural history and prognostic models in primary sclerosing cholangitis. , 2001, Best practice & research. Clinical gastroenterology.

[30]  S. Strom,et al.  Promiscuous regulator of xenobiotic removal , 2001, Nature Medicine.

[31]  R. Evans,et al.  An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Willson,et al.  The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[34]  K. Boberg,et al.  HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. , 1999, Tissue antigens.

[35]  E. Schrumpf,et al.  Relationship of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis , 1991, Seminars in liver disease.

[36]  R. Chapman,et al.  Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. , 1980, Gut.